Skip to main content

Holiday schedule

Our Patient Service Centers will be closed on Thursday, November 28, 2024 in observance of Thanksgiving. Have a healthy, happy holiday.

Hide
Quest Diagnostics

Aptima® HPV mRNA Genotyping

Genotyping for HPV types 16, 18/45

Cervical adenocarcinoma rates have been increasing for decades2

Aptima HPV mRNA assay genotyping includes genotype 45 to identify almost all HPV types associated with cervical adenocarcinoma. Evidence shows that the addition of HPV type 45 identifies more women at risk for adenocarcinoma with minimal impact to colposcopy rates.1

HPV type 45:

  • is only prevalent in 0.4% of women with normal cytology1
  • is the third most common HPV type in invasive cervical cancer; associated with 12% of adenocarcinomas1

Types 16, 18/45 show higher carcinogenic potential relative to all other high-risk HPV types.3

EXCELLENT SENSITIVITY

Aptima, along with Pap testing, has a combined sensitivity of over 99% for detecting cancer and high-grade cervical disease.4
Sensitivity
59771-Sensitivity-nurse@2x.png

BETTER SPECIFICITY VS DNA TESTING

With better specificity than HPV DNA testing, Aptima has been shown to reduce false positives and minimize unnecessary invasive procedures.4

Specificity
73207140

For more information

To set up testing, contact your sales representative or call 1.866.MYQUEST (1.866.697.8378).

You can also learn more about Aptima in our Test Directory.

Test Directory

The Aptima HPV assay detects E6/E7 viral mRNA from 14 high-risk types of human papillomavirus in cervical specimens (in ThinPrep® Pap Test vials containing PreservCyt® Solution and collected with broomtype or cytobrush/spatula devices). The test is indicated to screen women ≥21 years with ASCUS cytology to determine the need for colposcopy, and to screen women ≥30 years for high-risk HPV types. This information with cytology history, other risk factors, and guidelines may be used to manage patients. See www.genprobe.com for more details.
 

The assay is not a substitute for regular cervical cytology screening. The results of this test are not intended to prevent women from proceeding to colposcopy. The assay has not been evaluated for managing HPV vaccinated women, women with prior ablative or excisional therapy, hysterectomy, who are pregnant, or have other risk factors. Aptima and other associated logos are registered trademarks of Hologic, Inc., and/or its subsidiaries in the United States, and/or other countries.
 

References

 

  1. de Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11(11):1045-1056.
  2. Adegoke O, Kulasingam S, Virnig B. Cervical cancer trends in the United States: a 35-year population-based analysis. J Woman’s Health. 2012;21(10):1031-1037.
  3. Guan P, Howell-Jones R, Li N, et al. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer. 2012;131(10):2349-2359.
  4. Aptima HPV assay [package insert].

Co-testing solutions for

cervical cancer

Learn more about how Pap and HPV mRNA

testing work together to provide early

detection of cervical cancer.

Download Brochure

Aptima HPV RNA assay

Resources

The importance of screening for STIs

Clinical view on diagnostic strategies from AAFP for sexually transmitted infections: a 3-part webinar series

ReproSource: Quest Diagnostics Center of Excellence for fertility testing

Testing by trimester

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.